Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.

Skiriute D, Tamasauskas S, Asmoniene V, Saferis V, Skauminas K, Deltuva V, Tamasauskas A.

J Neurooncol. 2011 Mar;102(1):89-94. doi: 10.1007/s11060-010-0291-9. Epub 2010 Jul 4.

PMID:
20607352
2.

Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.

Trinkaus M, Vranic A, Dolenc VV, Lah TT.

Int J Biol Markers. 2005 Jan-Mar;20(1):50-9.

PMID:
15832773
3.

Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.

Bie L, Zhao G, Ju Y, Zhang B.

Cancer Genet. 2011 Oct;204(10):536-40. doi: 10.1016/j.cancergen.2011.08.019.

PMID:
22137483
4.

Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.

Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A.

Cancer Res. 2005 Aug 15;65(16):7121-6.

5.

Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.

Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Fèvre-Montange M.

Clin Neuropathol. 2008 Sep-Oct;27(5):334-45.

6.

Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.

Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A.

APMIS. 2009 Sep;117(9):651-9. doi: 10.1111/j.1600-0463.2009.02516.x.

PMID:
19703125
7.

Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.

Ruiz J, Martínez A, Hernández S, Zimman H, Ferrer M, Fernández C, Sáez M, López-Asenjo JA, Sanz-Ortega J.

Histol Histopathol. 2010 Mar;25(3):341-9.

PMID:
20054806
8.

Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.

Mihaila D, Jankowski M, Gutiérrez JA, Rosenblum ML, Newsham IF, Bögler O, Rempel SA; NABTT CNS Consortium.

Clin Cancer Res. 2003 Oct 1;9(12):4443-51.

9.

Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.

Aarhus M, Bruland O, Bredholt G, Lybaek H, Husebye ES, Krossnes BK, Vedeler C, Wester K, Lund-Johansen M, Knappskog PM.

J Neurooncol. 2008 Jul;88(3):251-9. doi: 10.1007/s11060-008-9569-6. Epub 2008 Mar 26.

PMID:
18365142
10.

P53 overexpression and proliferative potential in malignant meningiomas.

Nagashima G, Aoyagi M, Yamamoto M, Yamamoto S, Wakimoto H, Ohno K, Yamamoto K, Hirakawa K.

Acta Neurochir (Wien). 1999;141(1):53-61; discussion 60-1.

PMID:
10071687
11.

Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.

Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B.

Neuro Oncol. 2010 Dec;12(12):1278-90. doi: 10.1093/neuonc/noq081. Epub 2010 Aug 4.

12.

Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.

Ke HL, Ke RH, Li ST, Li B, Lu HT, Wang XQ.

J Neurooncol. 2013 Jun;113(2):327-32. doi: 10.1007/s11060-013-1121-7. Epub 2013 Mar 25.

PMID:
23525949
13.

Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.

Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V.

Pathol Res Pract. 2000;196(7):483-8.

PMID:
10926326
14.

Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.

Serna E, Morales JM, Mata M, Gonzalez-Darder J, San Miguel T, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Monleon D.

PLoS One. 2013 Jun 28;8(6):e67291. doi: 10.1371/journal.pone.0067291. Print 2013.

15.

The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.

Jiang J, Lin C, Liu N, Zhang Z, Sun Y, Fang X, Qi J.

APMIS. 2013 Oct;121(10):997-1003. doi: 10.1111/apm.12135. Epub 2013 Jul 24.

PMID:
23879478
16.

Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.

Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, Bertalanffy H.

Strahlenther Onkol. 2006 Nov;182(11):641-6.

PMID:
17072521
17.

Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.

Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B.

J Proteome Res. 2008 Jul;7(7):2882-8. doi: 10.1021/pr800110a. Epub 2008 May 29.

PMID:
18507434
18.

Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.

Ke HL, Ke RH, Li B, Wang XH, Wang YN, Wang XQ.

Acta Neurochir (Wien). 2013 Jan;155(1):165-71. doi: 10.1007/s00701-012-1512-0. Epub 2012 Oct 5.

PMID:
23053286
19.

Osteopontin predicts the behaviour of atypical meningioma.

Lin CK, Tsai WC, Lin YC, Hueng DY.

Histopathology. 2012 Jan;60(2):320-5. doi: 10.1111/j.1365-2559.2011.04085.x.

PMID:
22211290
20.

Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.

Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A.

Int J Oncol. 2009 Dec;35(6):1395-407.

PMID:
19885562
Items per page

Supplemental Content

Write to the Help Desk